<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00223509</url>
  </required_header>
  <id_info>
    <org_study_id>0340013418</org_study_id>
    <nct_id>NCT00223509</nct_id>
  </id_info>
  <brief_title>Lamictal As Add on Treatment in Mixed States of Bipolar Disorder</brief_title>
  <official_title>Lamictal As Add on Treatment in Mixed States of Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To evaluate the efficacy and safety of LAM+existing regimen of mood stabilizer in the&#xD;
           acute treatment of patients in a mixed state of bipolar disorder.&#xD;
&#xD;
        -  To evaluate the efficacy and of a combination of LAM+existing regimen of mood&#xD;
           stabilizers in the maintenance treatment of patients with mixed state of bipolar&#xD;
           disorder&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To evaluate the efficacy and safety of LAM+existing regimen of mood stabilizer in the&#xD;
           acute treatment of patients in a mixed state of bipolar disorder.&#xD;
&#xD;
        2. To evaluate the efficacy and of a combination of LAM+existing regimen of mood&#xD;
           stabilizers in the maintenance treatment of patients with mixed state of bipolar&#xD;
           disorder&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy, during the first 10 weeks (acute phase) of the study, will be assessed by the proportion of patients achieving a 50% reduction of their depressive symptoms as assessed by the MADRS and a GAF</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MADRS</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy, during the maintenance phase of the study, will be assessed by the proportion of patients able to maintain a response, at the end of the study, as defined by</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>MADRS total score of &lt;14, GAF score 51. Secondary measures will include the YMRS, and CGI Bipolar version.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary measures will include the YMRS, and CGI Bipolar version.</measure>
  </secondary_outcome>
  <enrollment type="Actual">28</enrollment>
  <condition>Bipolar Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        In order to be included in the study patient must meet criteria A, C, D, E, F, G plus any 1&#xD;
        of the 3 criteria listed in section B.&#xD;
&#xD;
        A. Patients meeting DSM-IV diagnosis of bipolar disorder, I or II&#xD;
&#xD;
        B.&#xD;
&#xD;
          1. Patients meeting DSM-IV diagnostic criteria for a manic/hypomanic episode with the&#xD;
             simultaneous presence of (or rapid alteration within minutes) of at least three DSM-IV&#xD;
             depressive symptoms excluding psychomotor agitation or&#xD;
&#xD;
          2. Patients meeting DSM-IV symptomatic criteria for a hypomanic/manic episode for a&#xD;
             period of 2 days or longer, with the simultaneous presence of (or rapid alteration&#xD;
             within minutes) of at least three DSM-IV depressive symptoms excluding psychomotor&#xD;
             agitation or&#xD;
&#xD;
          3. Patients meeting DSM-IV criteria for a depressive episode associated with at least&#xD;
             three DSM-IV manic/hypomanic symptoms&#xD;
&#xD;
        C.MADRS of ≥14&#xD;
&#xD;
        D.YMRS of ≥ 14&#xD;
&#xD;
        E. Age 13years to 75 years&#xD;
&#xD;
        F. Male or female&#xD;
&#xD;
        G. Outpatient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. illness precluding the use of LAM&#xD;
&#xD;
          2. Alcohol/drug dependence in the past one month&#xD;
&#xD;
          3. patients with a history of a rash on LAM&#xD;
&#xD;
          4. CNS neoplasms, demyelinating diseases, degenerative neurological condition or active&#xD;
             CNS infection&#xD;
&#xD;
          5. history of seizure, known EEG with frank paroxysmal activity, known CT of brain&#xD;
             showing gross structural abnormalities, cerebral vascular disease by history or&#xD;
             structural brain damage from trauma&#xD;
&#xD;
          6. patients currently taking LAM&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek - Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles L Bowden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>June 19, 2012</last_update_submitted>
  <last_update_submitted_qc>June 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mixed mania</keyword>
  <keyword>lamotrigine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

